OS outcomes for those diagnosed with metastatic HER2-positive breast cancer in 2012 or later are likely better; however, this is not fully reflected in our study’s survival estimates, which enrolled patients diagnosed from 2010 to 2020. Here, ERBB2 is linked to breast cancer.